Baricitinib, a Janus kinase 1/2 inhibitor approved by the FDA for the treatment of rheumatoid arthritis, was recently found to inhibit both AAK1 and GAK and used as a potential inhibitor for 2019-novel CoV acute respiratory disease (52). Here, GAK is linked to rheumatoid arthritis.